Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Gandhi, Leena; Rodríguez‐Abreu, Delvys; M. Gadgeel, Shirish; Esteban, Emilio; Felip, Enriqueta; De Angelis, Flávia; Dómine, Manuel; R. Clingan, Philip; J. Hochmair, Maximilian; Powell, Steven; Y. Cheng, Susanna; Bischoff, Helge; Peled, Nir; Grossi, Francesco; Jennens, Ross; Reck, Martin; Hui, Rina; B. Garon, Edward; Boyer, Michael; Rubio‐Viqueira, Belén; Novello, Silvia; Kurata, Takayasu; E. Gray, Jhanelle; Vida, John; Wei, Ziwen; Yang, Jing; Raftopoulos, Harry; Catherine Pietanza, M.; Chiara Garassino, Marina

doi:10.1056/nejmoa1801005

Public

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Published in New England Journal of Medicine • Apr 16, 2018

Authors:

Leena Gandhi

Delvys Rodríguez‐Abreu

Shirish M. Gadgeel

Abstract

BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as th...

Subject

Pembrolizumab

Chemotherapy

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!